Related Experiment Video

Updated: Sep 20, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K

The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective

Eseohi Ehimiaghe1, Nicole Marjon1, Miriam D Post2

  • 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

Gynecologic Oncology
|May 25, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Related Experiment Videos

Last Updated: Sep 20, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Targeting the MAT2A-SAM axis increases platinum sensitivity in ovarian cancer by impairing DNA repair and stemness.

bioRxiv : the preprint server for biology·2026

Minimally invasive hyperthermic intraperitoneal chemotherapy at the time of interval cytoreductive surgery for ovarian cancer: a case report.

Journal of surgical case reports·2026

Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.

Cell biomaterials·2026

Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma.

Cancer research communications·2026

Models of high-grade serous carcinoma of tubo-ovarian origin.

Oncology reviews·2026

The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.

Nature aging·2026

How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer.

Gynecologic oncology·2026

Implementation and sustainability of surgical randomized trials in gynecologic oncology: Adoption beyond publication.

Gynecologic oncology·2026

Clinical implications of germline and somatic genetic testing in ovarian carcinoma: BRCA and beyond. The PERSONA-Ovary trial.

Gynecologic oncology·2026

Trends in immunotherapy utilization among older adults with advanced endometrial cancer: An NCDB analysis.

Gynecologic oncology·2026

Immunoaffinity-enriched extracellular vesicle proteomics for high-grade serous ovarian cancer - A UKOPS nested case-control analysis.

Gynecologic oncology·2026

Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure.

Gynecologic oncology·2026

Calcineurin-mediated regulation of macrophage plasticity drives anti-tumor activity.

Molecular therapy. Advances·2026

EXO1 inhibition selectively kills replication repair-deficient cancer cells.

NAR cancer·2026

Biotics-based modulation of gastric precancerous states: microbial, metabolic, and epithelial mechanisms.

Frontiers in immunology·2026

Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.

Frontiers in cell and developmental biology·2026

DYRK1A - a gene dose paradox.

Frontiers in cell and developmental biology·2026

Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.

Theranostics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us